This comprehensive review discusses microbiome influence on lung cancer immunotherapy and predictive biomarkers, indicating novel approaches for personalized treatments.
Key Points
To explore the role of the microbiome as a predictor of immunotherapy outcomes in lung cancer.
Reviewed existing literature on microbiome profiles in lung cancer.
Investigated mechanisms of microbiome-tumor interactions.
Evaluated strategies for microbiome-targeted interventions.
Identified distinct microbiome profiles correlating with immunotherapy effectiveness.
Highlighted potential of microbial metabolites as predictive biomarkers.
Proposed future strategies for integrating microbiome insights in personalized treatment approaches.